a cure rate of 80 % with amikacin combination can be obtained , but , in vivo , resistant pathogens ( streptococcus , group d ) or poorly sensitive organisms ( pseudomonas aeruginosa + bacteroides fragilis : 1 case ) may be selected .
C0450254
pathogens
C0029235
organisms